(Q45870730)

17 December 2017

title

Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies (English)

1 reference

17 December 2017

author name string

Michinori Ogura

1

1 reference

17 December 2017

Kunihiro Tsukasaki

2

1 reference

17 December 2017

Hirokazu Nagai

3

1 reference

17 December 2017

Toshiki Uchida

4

1 reference

17 December 2017

Takashi Oyama

5

1 reference

17 December 2017

Tatsuya Suzuki

6

1 reference

17 December 2017

Jun Taguchi

7

1 reference

17 December 2017

Dai Maruyama

8

1 reference

17 December 2017

Tomomitsu Hotta

9

1 reference

17 December 2017

Kensei Tobinai

10

1 reference

17 December 2017

publication date

30 April 2012

1 reference

17 December 2017

published in

Cancer Science

1 reference

17 December 2017

volume

103

1 reference

17 December 2017

issue

7

1 reference

17 December 2017

page(s)

1290-1295

1 reference

17 December 2017

Forodesine: review of preclinical and clinical data

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02287.X

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02287.X

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02287.X

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02287.X

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02287.X

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02287.X

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02287.X

Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02287.X

Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma

21 January 2018

1 reference

12 December 2020

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

12 December 2020

Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma

1 reference

12 December 2020

Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).

1 reference

12 December 2020

Acute lymphoblastic leukemia

1 reference

12 December 2020

Purine nucleoside phosphorylase deficiency

1 reference

12 December 2020

10.1111/J.1349-7006.2012.02287.X

Identifiers

DOI

1 reference

17 December 2017

PMC publication ID

7659180

0 references

1 reference

17 December 2017